CD91:F:F-Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 28.565

Change

+0.68 (+2.44)%

Market Cap

USD 0.31B

Volume

525.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.18 (+0.65%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.41 (+0.80%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

+3.44 (+0.63%)

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.73 (-1.29%)

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.40 (+0.17%)

USD 57.94B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.15 (+0.98%)

USD 54.05B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.20 (+0.21%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.17 (+0.17%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 40.74B
0ZC:F Zscaler Inc

+0.76 (+0.50%)

USD 37.92B

ETFs Containing CD91:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.46% 94% A 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.46% 92% A 75% C
Trailing 12 Months  
Capital Gain 54.06% 95% A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.06% 93% A 80% B-
Trailing 5 Years  
Capital Gain 52.36% 69% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.36% 69% C- 57% F
Average Annual (5 Year Horizon)  
Capital Gain 1.89% N/A N/A 50% F
Dividend Return 1.89% N/A N/A 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.67% N/A N/A 70% C-
Risk Adjusted Return 10.69% N/A N/A 44% F
Market Capitalization 0.31B 49% F 43% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.